Continuous glucose monitoring may lower mortality risk in diabetic patients on insulin
People with type 2 diabetes (T2D) who began using continuous glucose monitoring (CGM) while receiving basal insulin had a 44% lower risk of dying from any cause after one year than those who did not use CGM, according to an analysis of patient data being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2. After two years,…
A study presented at the European Association for the Study of Diabetes meeting has found that continuous glucose monitoring (CGM) may significantly reduce mortality risk for patients with type 2 diabetes (T2D) who are using basal insulin. After one year, CGM users experienced a 44% lower risk of dying from any cause compared to non-CGM users, with the risk decreasing to 35% at two years.
The research, conducted using anonymized electronic health records from over 140 million Americans, suggests that CGM can improve long-term health outcomes for T2D patients on insulin therapy.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
